PT-141 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-08. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
There are also many references to the heart in the Christian Bible, including "Blessed are the pure in heart, for they will see God", "Above all else, guard your heart, for everything you do flows from it", "For where your treasure is, there your heart will be also", "For as a man thinks in his heart, so shall he be." The expression of a broken heart is a cross-cultural reference to grief for a lost one or to unfulfilled romantic love. The notion of "Cupid's arrows" is ancient, due to Ovid, but while Ovid describes Cupid as wounding his victims with his arrows, it is not made explicit that it is the heart that is wounded. The familiar iconography of Cupid shooting little heart symbols is a Renaissance theme that became tied to Valentine's Day. In certain Trans-New Guinea languages, such as Foi and Momoona, the heart and seat of emotions are colexified, meaning they share the same word.
Myotoxins are small, basic peptides found in rattlesnake and lizard (e.g. Mexican beaded lizard) venoms. This involves a non-enzymatic mechanism that leads to severe skeletal muscle necrosis. These peptides act very quickly, causing instantaneous paralysis to prevent prey from escaping and eventually death due to diaphragmatic paralysis. The first myotoxin to be identified and isolated was crotamine, discovered in the 1950s by Brazilian scientist José Moura Gonçalves from the venom of tropical South American rattlesnake Crotalus durissus terrificus. Its biological actions, molecular structure and gene responsible for its synthesis were all elucidated in the last two decades.
== Organs and tissues affected by IGF-1 == Since many distinct tissue types express the IGF-1 receptor, IGF-1's effects are diverse. It acts as a neurotrophic factor, inducing the survival of neurons. It may catalyse skeletal muscle hypertrophy, by inducing protein synthesis, and by blocking muscle atrophy. It is protective for cartilage cells, and is associated with activation of osteocytes, and thus may be an anabolic factor for bone. Since at high concentrations it is capable of activating the insulin receptor, it can also complement for the effects of insulin. Receptors for IGF-1 are found in vascular smooth muscle, while typical receptors for insulin are not found in vascular smooth muscle.
Subsequent research has found that the delayed dopaminergic phase is associated with the highly potent dopamine D4 receptor agonism of LSD's metabolite 13-hydroxy-LSD. The first phase is described as a "psychedelic experience", with "meaningfulness and portentousness" as the primary effects, while the latter phase is "clearly a paranoid state", including feeling "at the least self-centered, and usually suspicious, with ideas of reference or even paranoid convictions". The second phase typically develops about 4 to 6 hours after administration but at times up to 10 hours after administration. Parallels have been drawn between this phase and amphetamine psychosis. There is no indication that similar effects occur with other psychedelics like phenethylamines and simple tryptamines, which lack dopamine receptor agonism. The preceding findings have been described by researchers like Daniel X. Freedman and David E. Nichols.
== Sources == Clayton, W. Woodford; and Nelson, William. History of Bergen and Passaic Counties, New Jersey, with Biographical Sketches of Many of its Pioneers and Prominent Men., Philadelphia: Everts and Peck, 1882. Harvey, Cornelius Burnham (ed.), Genealogical History of Hudson and Bergen Counties, New Jersey. New York: New Jersey Genealogical Publishing Co., 1900. Van Valen, James M. History of Bergen County, New Jersey. New York: New Jersey Publishing and Engraving Co., 1900. Westervelt, Frances A. (Frances Augusta), 1858–1942, History of Bergen County, New Jersey, 1630–1923, Lewis Historical Publishing Company, 1923. Municipal Incorporations of the State of New Jersey (according to Counties) prepared by the Division of Local Government, Department of the Treasury (New Jersey); December 1, 1958.
Sources: en.wikipedia.org
In the United States, the FDA has approved pregabalin for adjunctive therapy for adults with partial onset seizures, management of postherpetic neuralgia and neuropathic pain associated with spinal cord injury and diabetic peripheral neuropathy, and the treatment of fibromyalgia. In Australia, the TGA has approved pregabalin for neuropathic pain in adults and epilepsy, it is not approved in Australia for generalized anxiety disorder or fibromyalgia. Pregabalin has also been approved in the European Union, the United Kingdom, and Russia for treatment of generalized anxiety disorder.
The brief existence of an mRNA molecule begins with transcription, and ultimately ends in degradation. During its life, an mRNA molecule may also be processed, edited, and transported prior to translation. Eukaryotic mRNA molecules often require extensive processing and transport, while prokaryotic mRNA molecules do not. A molecule of eukaryotic mRNA and the proteins surrounding it are together called a messenger RNP.
All high schools operate on an alternating A/B-day block scheduling system, where one group of classes are taken on "A-Days" and a different group of classes are taken on "B-Days," and the cycle repeats. Most high schools have between three and four lunch shifts, depending on enrollment and eating accommodations. The only exceptions are Eleanor Roosevelt High School — which has adopted a modified hybrid block schedule in which both traditional single period courses and double period (block schedule) courses are integrated — and the Academy of Health Science at Prince George's Community College.
Vision loss can occur and is associated with strabismus, refractive errors, and anisometropia. It can also be caused by severely dry eyes, a consequence of lower eyelid abnormalities and frequent eye infections. Although an abnormally shaped skull is not distinctive for Treacher Collins syndrome, brachycephaly with bitemporal narrowing is sometimes observed. Cleft palate is also common. Dental anomalies are seen in 60% of affected people, including tooth agenesis (33%), discoloration (enamel opacities) (20%), malplacement of the maxillary first molars (13%), and wide spacing of the teeth. In some cases, dental anomalies in combination with mandible hypoplasia result in a malocclusion. This can lead to problems with food intake and the ability to close the mouth. Less common features of TCS may add to an affected person's breathing problems, including sleep apnea. Choanal atresia or stenosis is a narrowing or absence of the choanae, the internal opening of the nasal passages, which may also be observed. Underdevelopment of the pharynx can also narrow the airway. Features related to TCS that are seen less frequently include nasal deformities, high-arched palate, macrostomia, preauricular hair displacement, cleft palate, hypertelorism, notched upper eyelid, and congenital heart defects. Although facial deformity is often associated with developmental delay and intellectual disability, more than 95% of people affected with TCS have normal intelligence. The psychological and social problems associated with facial deformity can affect quality of life in individuals with TCS.
=== Biomimetic mineralization === Biomolecules can be incorporated during the MOF crystallization process. Biomolecules including proteins, DNA, and antibodies could be encapsulated within ZIF-8. Enzymes encapsulated in this way were stable and active even after being exposed to harsh conditions (e.g. aggressive solvents and high temperature). ZIF-8, MIL-88A, HKUST-1, and several luminescent MOFs containing lanthanide metals were used for the biomimetic mineralization process. In addition, individual living cells were encapsulated within MOF shells via single-cell nanoencapsulation (SCNE).
Sources: en.wikipedia.org
The Ten Years' War ended in 1878, and the Spanish government authorized the creation of political parties in Cuba. Most of the leadership of the Grand Lodge of Colon at Havana were founding members of the Autonomist Liberal Party. Antonio Govín y Torres himself became the Secretary of the Autonomist Liberal Party. José María Gálvez became the Party President. Rafael Montoro, the intellectual leader of the party, also served as the Worshipful Master of Logia Plus Ultra (English: Plus Ultra Lodge). Other Freemasons became founding members of the Moderate Party of Cuba. On October 8, 1878, discussions opened on merging the Lodges of Colon Freemasonry and Cuban Freemasonry into a new unified body. The Little War occurred from 1879 to 1880. On either January 25, 1880 or March 25, 1880, the Grand Lodge of Colon at Havana and the Grand Lodge of Cuba, and 46 of their Lodges, merged to become the Gran Logia Unida de Colón y la Isla de Cuba (English United Grand Lodge of Colon and the Island of Cuba). After decades of multiple Grand Lodges and Grand Orients on the island, there was now a single and unified Grand Loge for the entire island of Cuba, with one Grand Master and two Deputy Grand Masters. The United Grand Lodge gained recognition from 34 foreign Masonic bodies. On September 4, 1881, 25 Lodges in Camagüey Province and Oriente Province accepted the authority and joined the United Grand Lodge. In 1881, seventy-one lodges operated in Cuba under the authority of the Grand Lodge.
The National Postgraduate Medical College of Nigeria (NPMCN): Established in 1979, NPMCN is responsible for the training and certification of medical and dental specialists within Nigeria. The West African Postgraduate Medical Colleges: These are the West African College of Physicians (WACP) and the West African College of Surgeons (WACS), which coordinate regional training and certification across West Africa.
== Chemical reactions == Due to its resonance stabilization, the peptide bond is relatively unreactive under physiological conditions, even less than similar compounds such as esters. Nevertheless, peptide bonds can undergo chemical reactions, usually through an attack of an electronegative atom on the carbonyl carbon, breaking the carbonyl double bond and forming a tetrahedral intermediate. This is the pathway followed in proteolysis and, more generally, in N–O acyl exchange reactions such as those of inteins. When the functional group attacking the peptide bond is a thiol, hydroxyl or amine, the resulting molecule may be called a cyclol or, more specifically, a thiacyclol, an oxacyclol or an azacyclol, respectively.
== History == Opipramol was developed by Geigy. It first appeared in the literature in 1952 and was patented in 1961. The drug was first introduced for use in medicine in 1961. Opipramol was one of the first TCAs to be introduced, with imipramine marketed in the 1950s and amitriptyline marketed in 1961.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.